• 生物活性

靶点及简介 ：A humanized anti-PD-L1 monoclonal antibody,Durvalumab (anti-PD-L1)是一种IgG1κ单抗，抑制PD-L1与PD-1/CD80 (B7.1)的相互作用。MW=146.3 kDa。

Durvalumab (MEDI 4736) 是一种人源化的抗 PD-L1 蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断 PD-L1 与 PD-1 和 CD80 结合， IC50 分别为 0.1 和 0.04 nM。

Evolocumab 是人源化单克隆抗体PCSK9的抑制剂。它与循环的 PCSK9 蛋白结合，使得PCSK9与 LDLR 结合受到抑制。它可用研究于高胆固醇血症以及动脉粥样硬化性心血管疾病的研究。

体外研究    

The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.[2]

体内研究    

The peak tumor uptake of 124I-Durva-F(ab’)2 was close to 124I-Durva, but much earlier (5.29±0.42% ID/g for 124I-Durva-F(ab’)2 at 12 h vs 5.18±0.73% ID/g for 124I-Durva at 48 h). Compared with 124I-Durva, an accelerated blood clearance was observed for 124I-Durva-F(ab’)2, allowing for a higher tumor-to-background ratio.[2]

• 验证及参考文献

验证：

参考文献：

[1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.

• [2] Cheng Y, et al. Mol Pharm. 2022 Mar 4.

关键词：度伐单抗；德瓦鲁单抗，Durvalumab, MEDI 4736, Durvalumab供应商, PD-1/PD-L1抑制剂, 购买Durvalumab, Durvalumab溶解度, Durvalumab结构式